Katherine Stueland sold $2.0M of WGS
CHIEF EXECUTIVE OFFICER at GeneDx Holdings Corp.. 25,459 shares at an average of $78.61, traded Mar 4, 2026, filed Mar 5, 2026.
Score components
- +25RoleCEO
- +25Trade size$2.0M at market
- +10Share of holdings soldSold 40% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001689575-26-000010, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 3, 2026 | AGrant or award Class A Common Stock | +47,684 | $0.00 | $0 | 64,142 | Mar 5, 2026 |
| Mar 4, 2026 | SOpen-market sale Class A Common Stock | -5,861 | $77.63 | $455k | 58,281 | Mar 5, 2026 |
| Mar 4, 2026 | SOpen-market sale Class A Common Stock | -10,465 | $78.61 | $823k | 47,816 | Mar 5, 2026 |
| Mar 4, 2026 | SOpen-market sale Class A Common Stock | -9,133 | $79.25 | $724k | 38,683 | Mar 5, 2026 |
| Mar 3, 2026 | AGrant or award Restricted Stock Unitderivative | +40,418 | $0.00 | $0 | 40,418 | Mar 5, 2026 |
Related signals
Other insiders at GeneDx Holdings Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $364k 3,728 shares | -8% | |
| 43Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.0M 10,501 shares | -8% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $108k 1,285 shares | -3% | |
| 32Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $311k 3,692 shares | -3% | |
| 20Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $31k 372 shares | -1% | |
| 39Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $557k 8,818 shares | -20% | |
| 53Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $3.0M 46,933 shares | -34% | |
| 37Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $438k 5,706 shares | -17% | |
| 48Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.3M 17,179 shares | -23% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $111k 1,280 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.